TiHKAL

Last updated

TiHKAL: The Continuation
Tihkal.jpg
Cover of TiHKAL, 1st ed.
Author Alexander and Ann Shulgin
Subject Pharmacology, Autobiography, Psychedelic drugs
Publisher Transform Press
Publication date
1997
Publication placeUnited States
Media typePaperback
Pagesxxviii, 804 p.
ISBN 0-9630096-9-9
OCLC 38503252
Preceded by PiHKAL (1991) 

TiHKAL: The Continuation, also known as Tryptamines I Have Known and Loved, is a 1997 book written by Alexander Shulgin and Ann Shulgin. [1] [2] It is about a family of psychoactive drugs known as tryptamines, which includes psychedelics, other hallucinogens, and entactogens. [1] [2] The book has two halves, and the second part of the book contains detailed entries on 55 tryptamines. [2] TiHKAL is a sequel to PiHKAL: A Chemical Love Story (Phenethylamines I Have Known and Loved) (1991). [1] [2]

Contents

Content

TiHKAL, much like its predecessor PiHKAL , is divided into two parts. [2] The first part, for which all rights are reserved, begins with a fictionalized autobiography, picking up where the similar section of PiHKAL left off; it then continues with a collection of essays on topics ranging from psychotherapy and the Jungian mind to the prevalence of DMT in nature, ayahuasca and the war on drugs. [2]

The second part of TiHKAL, which may be conditionally distributed for non-commercial reproduction (see § External links, below), is a detailed synthesis manual for 55 tryptamines (many discovered by Alexander Shulgin himself), including their chemical structures, doses, durations, and commentary. [2] It includes entries on compounds including simple tryptamines like dimethyltryptamine (DMT), psilocin, and 5-MeO-DMT, α-alkyltryptamines like α-methyltryptamine (AMT), β-carbolines or harmala alkaloids like harmaline, the iboga alkaloid ibogaine, and lysergamides like LSD. [2] Whereas PiHKAL had 179 entries on phenethylamines, TiHKAL has only 55 entries. [3] [2] Shulgin has made the second part freely available on Erowid while the first part is available only in the printed text.

Members of Shulgin's research who contributed to the experience reports included Shulgin himself, Ann Shulgin, Myron Stolaroff, and Jean Stolaroff, among others. [4] [5]

Response

As with PiHKAL , the Shulgins were motivated to release the synthesis information as a way to protect the public's access to information about psychedelic compounds, a goal Alexander Shulgin has noted many times. [6] Following a raid of his laboratory in 1994 by the United States DEA, [7] Richard Meyer, spokesman for DEA's San Francisco Field Division, stated that "It is our opinion that those books [referring to the previous work, PiHKAL are pretty much cookbooks on how to make ‘controlled drugs’. Agents tell me that in clandestine labs that they have raided, they have found copies of those books."

Notable compounds

Some compounds in TiHKAL, including dimethyltryptamine (DMT), psilocybin (4-PO-DMT), psilocin (4-HO-DMT), bufotenin (5-HO-DMT), 5-MeO-DMT, α-methyltryptamine (AMT), lysergic acid diethylamide (LSD), harmaline, and ibogaine, are widely known and/or used hallucinogens. [2]

Tryptamines listed

In addition to TiHKAL, Shulgin has also described the properties of psychedelic tryptamines in humans in literature reviews. [9] [10] [11] [12] [13]

See also

References

  1. 1 2 3 Ben Sessa (2015). "Continuing History of Psychedelics in Medical Practices: The Renaissance of Ps chedelic Medical Research". In Ellens, J.H.; D, T.B.R.P. (eds.). The Psychedelic Policy Quagmire: Health, Law, Freedom, and Society. Psychology, Religion, and Spirituality. Bloomsbury Publishing. p. 50. ISBN   979-8-216-13356-8 . Retrieved January 30, 2025.
  2. 1 2 3 4 5 6 7 8 9 10 Alexander T. Shulgin; Ann Shulgin (1997). TiHKAL: The Continuation (1st ed.). Berkeley, CA: Transform Press. ISBN   978-0-9630096-9-2. OCLC   38503252 . Retrieved January 30, 2025.
  3. ↑ Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628.
  4. ↑ Connie Littlefield (director, writer), Siobhan Flanagan, Alexander Shulgin (subject), Ann Shulgin (subject), Paul F. Daley (subject), Myron Stolaroff (subject), Jean Stolaroff (subject), Wendy Perry Tucker (subject), Tania Manning (subject), Greg Manning (subject), Keeper Trout (subject), Earth and Fire Erowid, others (2021). Better Living Through Chemistry (Motion picture). Better Living Through Film, Incorporated. Archived from the original on September 21, 2021.
  5. ↑ Passie T, Brandt SD (2018). "Self-Experiments with Psychoactive Substances: A Historical Perspective". Handb Exp Pharmacol. 252: 69–110. doi:10.1007/164_2018_177. PMID   30478735. More ambitious explorations of subjective effects elicited by a series of new psychoactive substances developed by Shulgin were conducted by his close associate and psychologist, Myron Stolaroff. Following SEs with LSD in the mid-1950s, Stolaroff became involved in scientific research on psychedelics. After the control of most psychedelic drugs in the 1970s, Stolaroff conducted SEs with newly synthesized psychedelics 2C-B, 2C-E, 2C-T-2, 2C-T-7, 2C-T4, 2C-T-21, and MEM but also MDMA. Besides Shulgin, Stolaroff was the first who systematically explored the psychological states and their possible uses but under noncontrolled conditions (Stolaroff 1994). He understood his research as an attempt "to make the unconscious conscious" and to give some "guidelines for the proper and safe use of psychedelic drugs in therapy and for spiritual growth" (Stolaroff 1994, pp. 13–14).
  6. ↑ Bennett, Drake (January 30, 2005). "Dr. Ecstasy". New York Times Magazine. Retrieved July 8, 2006.
  7. ↑ "DEA Raid of Shulgin's Laboratory". Erowid. January 8, 2004. Retrieved July 8, 2006.
  8. ↑ Morris H, Smith A (May 2, 2010). "The Last Interview With Alexander Shulgin". VICE.
  9. ↑ Jacob P, Shulgin AT (1994). "Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.). Hallucinogens: An Update (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91. PMID   8742795. Archived from the original on July 13, 2025.
  10. ↑ Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN   978-0-12-433951-4. Archived from the original on July 13, 2025.
  11. ↑ Shulgin AT (1978). "Psychotomimetic Drugs: Structure-Activity Relationships". In Iversen LL, Iversen SD, Snyder SH (eds.). Stimulants. Boston, MA: Springer US. pp. 243–333. doi:10.1007/978-1-4757-0510-2_6. ISBN   978-1-4757-0512-6.
  12. ↑ Shulgin AT (1980). "Hallucinogens". In Burger A, Wolf ME (eds.). Burger's Medicinal Chemistry. Vol. 3 (4 ed.). New York: Wiley. pp. 1109–1137. ISBN   978-0-471-01572-7. OCLC   219960627.
  13. ↑ Shulgin AT (1982). "Chemistry of Psychotomimetics". In Hoffmeister F, Stille G (eds.). Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs. Handbook of Experimental Pharmacology. Vol. 55. Berlin: Springer Berlin Heidelberg. pp. 3–29. doi:10.1007/978-3-642-67770-0_1. ISBN   978-3-642-67772-4. OCLC   8130916.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.